This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

CVS/pharmacy® Reminds Patients With Diabetes About The Importance Of Regular Testing To Help Manage Their Disease

Stocks in this article: CVS

WOONSOCKET, R.I., May 20, 2013 /PRNewswire/ -- CVS/pharmacy is reminding patients with diabetes that one of the most important ways they can manage their disease is to perform regular testing of their blood sugar (glucose) levels. While the number of providers that will accept Medicare coverage for diabetes testing supplies is expected to decline after July 1, 2013 due to Medicare changes, CVS/pharmacy is informing those treating diabetes it will continue to accept Medicare Part B coverage for test strips and other diabetes testing supplies. The Company has more than 7,400 locations in the U.S. and stocks all major brands of diabetes supplies.

(Logo: )

"More than 25 million people in the United States have diabetes and every 17 seconds, another American is diagnosed with diabetes, so it is critical that patients continue to have affordable access to diabetes testing supplies to help them manage their disease," said Papatya Tankut, RPh, Vice President of Pharmacy Affairs at CVS Caremark. "CVS/pharmacy is committed to ensuring that Medicare patients can use their insurance coverage for test strips and other diabetes supplies. We also offer 90-day supplies of prescription test strips at the same low price as mail order."

CVS pharmacists are available every day as a resource for patients with diabetes who need advice or who have questions about prescription and over the counter medications to manage their disease. CVS/pharmacy can also assist patients with any new paperwork from their doctor's office that is required by the changes Medicare is making to coverage of diabetes testing supplies.  

Another resource CVS/pharmacy offers patients with diabetes is the ExtraCare Advantage for Diabetes ® program, which has helped more than 2 million members save money and better manage the disease since 2010. The program is free and open to all members of the CVS/pharmacy ExtraCare savings and rewards program. Cardholders can easily sign up at Once enrolled, patients and caregivers can earn double ExtraBucks ® Rewards on more than 100 products used to manage diabetes, and receive additional offers through an online newsletter and register receipts. Members can also log on to or access the  CVS mobile app to view personalized ExtraSavings and ExtraBucks Rewards that are available, and choose to "Print" or "Send to Card" their coupon savings and ExtraBucks   Rewards. 

About CVS/pharmacy

CVS/pharmacy, the retail division of CVS Caremark Corporation (NYSE: CVS), is America's leading retail pharmacy with more than 7,400 CVS/pharmacy and Longs Drug stores. CVS/pharmacy is reinventing pharmacy to help people on their path to better health by providing the most accessible and personalized expertise, both in its stores and online at General information about CVS/pharmacy and CVS Caremark is available at

MEDIA CONTACT: Mike DeAngelis michael.deangelis@cvscaremark.com401.770.2645

SOURCE CVS/pharmacy

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs